Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Cryotherapy for Bronchoscopic Management of Central Airway Obstruction: Clinical Experience at Assiut University Hospital.

2026. november 16. frissítette: Ebtesam Adel Hammad Askar, Assiut University

The aim of this study is to evaluate the clinical efficacy of therapeutic bronchoscopic cryotherapy for management of central airway obstruction (CAO).

A tanulmány áttekintése

Részletes leírás

Introduction:

Central airway obstruction (CAO) is defined as significant narrowing of the trachea, main stem bronchi or the bronchus intermedius, and occurs in a wide variety of airway disorders, including endobronchial tumors, post-intubation and post-tracheostomy stenosis, post-infectious stenosis, granulation tissue, tracheomalacia, and foreign body obstruction . It is associated with a poor prognosis and impaired quality of life, even when the underlying cause is benign.

Therapeutic bronchoscopy can improve symptoms, quality of life, and survival in patients with CAO, and the current American College of Chest Physicians guideline supports a multimodality approach that includes tissue debridement, ablation, dilation, and stent placement according to the underlying disease . Recent evidence shows substantial improvements in breathlessness and quality of life after therapeutic airway interventions, with a low complication rate in a large long-term series.

Bronchoscopic cryotherapy is a pragmatic modality for recanalization of CAO that can be delivered through a flexible bronchoscope under moderate sedation, achieving more than partial airway patency in about 90% of sessions in an 11-year single-center cohort, although bleeding remains the main concern [7]. Its usefulness has also been shown in tumor-like endobronchial tuberculosis and, with the spray technique, in a prospective registry of central airway diseases . In Egypt, a single-center study reported that cryotherapy was safe and improved clinical scores, pulmonary function, and quality of life in patients with CAO of different etiologies . Evidence regarding bronchoscopic cryotherapy for CAO remains limited in our region despite its increasing clinical utilization. This study aims to assess the feasibility, safety, and clinical outcomes of bronchoscopic cryotherapy for CAO within the constraints of a resource-limited healthcare environment and evaluating our institutional experience at Assiut University Hospital.

  • The aim of this study is to evaluate the clinical efficacy of therapeutic bronchoscopic cryotherapy for management of central airway obstruction (CAO).

  • Type of the study: Prospective Interventional Study.

  • Study Group: The study will include patients diagnosed with central airway obstruction (CAO) and fit for bronchoscopy.

  • Study Setting: Respiratory bronchoscopy unit, Assuit University Hospital. Study subjects: All adult patients diagnosed with central airway obstruction(CAO) and fit for bronchoscopic intervention will be eligible.

    a. Inclusion criteria:

    • Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy
    • b. Exclusion criteria:
    • Patients with coagulopathy (INR > 1.5).
    • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
    • Severe pulmonary hypertension (PASP > 55 mmHg).
    • Hemodynamic instability.
    • Lung collapse > 2 months duration. c.Sample size calculation:

The sample size was calculated using Epi Info™️ version 7 software based on the following assumptions:

The primary outcome variable was the successful airway recanalization rate. Based on a previous study by Hussein et al. (2026), the overall successful recanalization rate (complete and partial) was 96%. Assuming an expected proportion of 96%, a confidence level of 90%, and a confidence limit (margin of error) of 5%, the minimum required sample size was estimated to be 42.

  • Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …):

Baseline Evaluation

Prior to the intervention, all candidates will undergo:

  • Clinical Assessment: Detailed history taking, physical examination, and dyspnea assessment using the modified Medical Research Council (mMRC) scale, while cough and hemoptysis were evaluated using the Walsh cough score and the Morice hemoptysis severity score, respectively.

  • Laboratory Tests: CBC, liver/kidney functions, coagulation profile, fasting blood glucose, and Arterial Blood Gases (ABG)

  • Radiological Imaging: Plain Chest X-ray (PA view) and CT chest to evaluate the site and extent of the obstruction.

  • Functional assessment : ABG and pulmonary function test pre and post procedure. Intervention Protocol (Therapeutic Bronchoscopy)

    1. General Preparation

  • Anesthesia: This procedure will be performed under local anesthesia .

  • Equipment: A flexible bronchoscope (e.g., Pentax EBK-3000) with a 3.2 mm working channel.

  • Pre-medication: Intramuscular atropine (0.5 mg) to reduce secretions and prevent vasovagal reflexes and nebulized lidocaine.

  • Mapping: Determination of the location and degree of obstruction according to the Freitag et al [8]. scheme.

    1. Specific Techniques

Bronchoscopic Cryotherapy (ERBOKRYO CA):

In a well-equipped room with monitoring of blood pressure ,heart rate ,respiratory rate and oxygen saturation.

  • Mechanism: Utilizing the Joule-Thompson effect, where high-pressure (60 bar) carbon dioxide as a cooling agent rapidly expands at the probe tip due to the difference with the atmospheric pressure, reducing the temperature to approximately - 78 °C [9].
  • Application: Procedures will be conducted under local aesthesia in one or two sessions, each lasting 30-60 min. The cryo¬probe will be inserted through the bronchoscope biopsy channel which is positioned approximately 10 mm above the lesion and the probe is in direct contact to the lesion. The lesion will be frozen for 20-60 s/cycle for three cycles to devascularize the tumor, after which the bronchoscope and cryoprobe will be removed together with adherent tissue.

IV. Follow-up Parameters

  • Immediate (Post-procedure): Chest X-ray within 2 hours to exclude pneumothorax.
  • Short-term: Monitoring for peri-procedural complications within the first 24 hours Complications were classified as minor (e.g., self-limited bleeding, transient hypoxemia, mild pneumomediastinum not requiring invasive intervention) or major (e.g., life-threatening bleeding, respiratory failure requiring ventilatory support, pneumothorax requiring chest tube insertion).This classification was conceptually aligned with the Common Terminology Criteria for Adverse Events (CTCAE) framework.
  • Bronchoscopic grading of bleeding severity; Grade 1: Bleeding requiring suctioning for less than 1 minute. Grade 2: Bleeding requiring suctioning for more than 1 minute, repeated wedging of the bronchoscope, or topical haemostatic agents.

Grade 3: Bleeding requiring selective intubation with an endotracheal tube or balloon/bronchial blocker for less than 20 minutes, or premature termination of the procedure.

Grade 4: Persistent selective intubation for more than 20 minutes, ICU admission, transfusion, bronchial artery embolisation, or resuscitation.

- Long-term: Patients will be followed for up to 3 months post-procedure, including:

  • Clinical evaluation ;

    - Quality of life (SF-36),symptoms(cough,dyspnea,hemoptysis).

  • Functional Evaluation ; ABG and spirometry.

  • Bronchoscopic evaluation (to check for re-obstruction)if clinically indicated.

  • Radiological evaluation (CT or Chest X-ray).

    • Research outcome measures:

      1. Primary (main):

Technical efficacy: Percentage of patients achieving successful airway recanalization following bronchoscopic cryotherapy, according to the Freitag et al & Hussein et al :

  1. Complete canalization: ≥90% restoration of airway lumen
  2. Partial canalization: 50-89% restoration.
  3. Failed canalization: <50% restoration or inability to proceed due to complications

b. Secondary (subsidiary):

  1. Symptomatic Improvement: Changes in dyspnea (mMRC scale),cough and hemoptysis score evaluated at short-term and at the 3-month follow-up.
  2. Safety Profile: incidence of minor and major peri-procedural complications within 24 hours, categorized using the Common Terminology Criteria for Adverse Events (CTCAE) framework.
  3. Long-term Airway Patency: Rate of re-obstruction and CAO-related re-hospitalization during the 3-month follow-up period.
  4. Overall Survival: Estimation of the 1-year overall survival (OS) rate post-intervention

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

42

Fázis

  • Nem alkalmazható

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

  • Név: Ebtesam Adel Hammad Askar, Assistant Lecturer
  • Telefonszám: +2001012089691
  • E-mail: ebtesam6569@gmail.com

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év és régebbi (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

• Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy.

Exclusion Criteria:

  • Patients with coagulopathy (INR > 1.5).
  • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
  • Severe pulmonary hypertension (PASP > 55 mmHg).
  • Hemodynamic instability.
  • Lung collapse > 2 months duration

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: N/A
  • Beavatkozó modell: Egyetlen csoportos hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: All adult patients diagnosed with CAO and fit for bronchoscopic intervention

Study subjects: All adult patients diagnosed with CAO and fit for bronchoscopic intervention will be eligible.

a. Inclusion criteria:

  • Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy
  • b. Exclusion criteria:
  • Patients with coagulopathy (INR > 1.5).
  • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
  • Severe pulmonary hypertension (PASP > 55 mmHg).
  • Hemodynamic instability.
  • Lung collapse > 2 months duration.

Intervention Protocol (Therapeutic Bronchoscopy)

  1. General Preparation

    • Anesthesia: This procedure will be performed under local anesthesia .
    • Equipment: A flexible bronchoscope (e.g., Pentax EBK-3000) with a 3.2 mm working channel.
    • Pre-medication: Intramuscular atropine (0.5 mg) to reduce secretions and prevent vasovagal reflexes and nebulized lidocaine.
    • Mapping: Determination of the location and degree of obstruction according to the Freitag et al [8]. scheme.

3. Specific Techniques

Bronchoscopic Cryotherapy (ERBOKRYO CA):

In a well-equipped room with monitoring of blood pressure ,heart rate ,respiratory rate and oxygen saturation.

  • Mechanism: Utilizing the Joule-Thompson effect, where high-pressure (60 bar) carbon dioxide as a cooling agent rapidly expands at the probe tip due to the difference with the atmospheric pressure, reducing the temperature to approximately - 78 °C [9].
  • Application: Procedures will be conducted under local aesthesia

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
percentage of patients achieving central airway recanalization.
Időkeret: Follow up after 3 months

Successful airway recanalization following therapeutic bronchoscopic cryotherapy for central airway obstruction (CAO), defined according to the Freitag et al. and Hussein et al. criteria.

Follow up after 3 months

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Change in Dyspnea Severity.
Időkeret: baseline and at 3 months follow up

Change from baseline in dyspnea evaluated using the modified Medical Research Council (mMRC) dyspnea scale (score range 0 to 4, where higher scores indicate worse dyspnea).

baseline and at 3 months follow up
Change in Cough Score
Időkeret: baseline and at 3 months follow up period

Change from baseline according to walsh cough score

baseline and at 3 months follow up period
Change in Hemoptysis Score
Időkeret: baseline and at 3 months follow up period

Change from baseline according to morice hemoptysis score

baseline and at 3 months follow up period
Incidence of Minor and Major Peri-procedural Complications
Időkeret: Within 24 hours post-procedure

Number of participants with treatment-related adverse events and complications, categorized by severity using the Common Terminology Criteria for Adverse Events (CTCAE) framework.

Within 24 hours post-procedure
Rate of Airway Re-obstruction and CAO-related Re-hospitalization
Időkeret: up to 3 months

Percentage of patients experiencing symptomatic airway re-obstruction or requiring re-hospitalization related to central airway obstruction (CAO).

up to 3 months
1-Year Overall Survival (OS) Rate
Időkeret: 1 year

Percentage of participants alive at 1 year following the bronchoscopic cryotherapy intervention.

1 year

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2026. november 10.

Elsődleges befejezés (Becsült)

2027. november 10.

A tanulmány befejezése (Becsült)

2028. november 10.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. november 3.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 16.

Első közzététel (Tényleges)

2026. november 18.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 18.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 16.

Utolsó ellenőrzés

2026. november 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

További vonatkozó MeSH feltételek

Egyéb vizsgálati azonosító számok

  • AssiutU-med-2026

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

NEM

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel